These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 14515265)

  • 1. The influence of CD95L expression on tumor rejection in mice.
    Igney FH; Behrens CK; Krammer PH
    Eur J Immunol; 2003 Oct; 33(10):2811-21. PubMed ID: 14515265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo.
    Igney FH; Behrens CK; Krammer PH
    Int J Cancer; 2005 Jan; 113(1):78-87. PubMed ID: 15386427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
    Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
    J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
    Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
    Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
    Ryan AE; Shanahan F; O'Connell J; Houston AM
    Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of FasL on inflammation and tumor survival are dependent on its expression levels.
    Wada A; Tada Y; Kawamura K; Takiguchi Y; Tatsumi K; Kuriyama T; Takenouchi T; O-Wang J; Tagawa M
    Cancer Gene Ther; 2007 Mar; 14(3):262-7. PubMed ID: 17053813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular localization and function of Fas ligand (CD95L) in tumors.
    Kurooka M; Nuovo GJ; Caligiuri MA; Nabel GJ
    Cancer Res; 2002 Mar; 62(5):1261-5. PubMed ID: 11888887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-dependent tumor rejection and priming of tumoricidal CD8+ T cell response induced by dendritic cells overexpressing CD95L.
    Buonocore S; Haddou NO; Moore F; Florquin S; Paulart F; Heirman C; Thielemans K; Goldman M; Flamand V
    J Leukoc Biol; 2008 Sep; 84(3):713-20. PubMed ID: 18567840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege.
    Gregory MS; Koh S; Huang E; Saff RR; Marshak-Rothstein A; Mukai S; Ksander BR
    Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2495-502. PubMed ID: 15980241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of Fas ligand as an effector molecule in corneal graft rejection.
    Stuart PM; Yin X; Plambeck S; Pan F; Ferguson TA
    Eur J Immunol; 2005 Sep; 35(9):2591-7. PubMed ID: 16114107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the proinflammatory effects of Fas ligand (CD95L).
    Chen JJ; Sun Y; Nabel GJ
    Science; 1998 Nov; 282(5394):1714-7. PubMed ID: 9831564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor counterattack: fact or fiction?
    Igney FH; Krammer PH
    Cancer Immunol Immunother; 2005 Nov; 54(11):1127-36. PubMed ID: 15889255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells.
    Imai T; Adachi S; Nishijo K; Ohgushi M; Okada M; Yasumi T; Watanabe K; Nishikomori R; Nakayama T; Yonehara S; Toguchida J; Nakahata T
    Oncogene; 2003 Dec; 22(58):9231-42. PubMed ID: 14647441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of CXC chemokines and macrophages in the recruitment of inflammatory cells and tumor rejection induced by Fas/Apo-1 (CD95) ligand-expressing tumor.
    Shimizu M; Yoshimoto T; Sato M; Morimoto J; Matsuzawa A; Takeda Y
    Int J Cancer; 2005 May; 114(6):926-35. PubMed ID: 15645421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo- and xenografts.
    Seino K; Kayagaki N; Tsukada N; Fukao K; Yagita H; Okumura K
    Transplantation; 1997 Oct; 64(7):1050-4. PubMed ID: 9381528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations of CD95 ligand-transduced killer dendritic cells to prevent graft rejections.
    Kusuhara M; Matsue H
    Exp Dermatol; 2005 Apr; 14(4):273-80. PubMed ID: 15810885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
    Modiano JF; Sun J; Lang J; Vacano G; Patterson D; Chan D; Franzusoff A; Gianani R; Meech SJ; Duke R; Bellgrau D
    Clin Immunol; 2004 Jul; 112(1):54-65. PubMed ID: 15207782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
    Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
    Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of Fas-L in glioma cells by ribozyme reduces cell apoptosis, tumour-infiltrating cells, and liver damage but accelerates tumour formation in nude mice.
    Chio CC; Wang YS; Chen YL; Lin SJ; Yang BC
    Br J Cancer; 2001 Oct; 85(8):1185-92. PubMed ID: 11710833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of CD95L fusion protein prodrugs by tumor-associated proteases.
    Watermann I; Gerspach J; Lehne M; Seufert J; Schneider B; Pfizenmaier K; Wajant H
    Cell Death Differ; 2007 Apr; 14(4):765-74. PubMed ID: 17053806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.